A5037427063- Bone health and osteoporosis research
- Hip and Femur Fractures
- Bone Metabolism and Diseases
- Vitamin D Research Studies
- Bone health and treatments
- Bone and Joint Diseases
- Hip disorders and treatments
- Global Cancer Incidence and Screening
- Meta-analysis and systematic reviews
- Growth Hormone and Insulin-like Growth Factors
- Colorectal Cancer Screening and Detection
- Nutrition and Health in Aging
- Menopause: Health Impacts and Treatments
- Vitamin C and Antioxidants Research
- Molecular Biology Techniques and Applications
- Health and Medical Research Impacts
- Smoking Behavior and Cessation
- Cancer Risks and Factors
- Genetics and Physical Performance
- Estrogen and related hormone effects
- Nutrition, Genetics, and Disease
- Pancreatitis Pathology and Treatment
- Health Promotion and Cardiovascular Prevention
- Osteoarthritis Treatment and Mechanisms
- Healthcare cost, quality, practices
University of North Carolina at Chapel Hill
2013-2023
Boston Scientific (United States)
2020-2022
RTI International
2018
Cleveland Clinic
2014
Day Family Medicine
2002-2011
North Carolina Division of Public Health
2008
Robert Wood Johnson Foundation
2003-2005
University of California, San Diego
2001
Georgetown University
2001
Although bone mineral density (BMD) testing to screen for osteoporosis (BMD T score, −2.50 or lower) is recommended women 65 years of age older, there are few data guide decisions about the interval between BMD tests.
Claims about the diagnostic or prognostic accuracy of markers often prove disappointing when "discrimination" found between cancers versus normals is due to bias, a systematic difference compared groups. This article describes framework help simplify and organize current problems in marker research by focusing on role specimens as source bias observational using that focus address improve reliability. The central idea "fundamental comparison" (ie, comparison done assess whether...
Risk indices have been developed to identify women at risk of low bone mineral density (BMD) who should undergo BMD testing.To compare the performance four in White ambulatory Belgium.Epidemiological cross-sectional study.Records were analysed for 4035 postmenopausal without Paget's disease or advanced osteoarthritis, seen an out-patient osteoporosis centre between January 1996 and September 1999. Osteoporosis index scores compared T-scores. The ability each with (T-score < -2.0) (T -2.5)...
ABSTRACT The US Preventive Services Task Force (USPSTF) recommends osteoporosis screening for women younger than 65 years whose 10-year predicted risk of major osteoporotic fracture is ≥9.3%. For identifying candidates among aged 50 to 64 years, it uncertain how the USPSTF strategy compares with Osteoporosis Self-Assessment Tool (OST) and Simple Calculated Risk Estimate (SCORE). We examined data (1994 2012) from 5165 Women's Health Initiative participants years. (Fracture Assessment [FRAX]...
The United States Preventive Services Task Force (USPSTF) recommends osteoporosis screening for women younger than 65 years whose 10-year predicted risk of major osteoporotic fracture (MOF) is at least 9.3% using the Fracture Risk Assessment Tool. In postmenopausal age 50-64 old, it uncertain how USPSTF strategy compares with Osteoporosis Self-Assessment Tool and Simple Calculated Estimate (SCORE) in discriminating who will not experience MOF. This study aimed to assess sensitivity,...
The American College of Rheumatology (ACR) updated its guidelines on the prevention and treatment glucocorticoid-induced osteoporosis (GIO) in 2010. An unknown proportion US adults at risk fracture due to glucocorticoid use would be recommended antiosteoporosis pharmaceutical (AOP) therapies based ACR guidelines.Using 2005-2010 National Health Nutrition Examination Survey (NHANES) data for postmenopausal women (PMW), men age ≥50 years reporting current use, we categorized individuals...
ABSTRACT To determine the association of weight loss with risk clinical fractures at hip, spine, and pelvis (central body [CBFs]) in older men without accounting for competing mortality, we used data from 4523 (mean age 77.5 years). Weight change between baseline follow-up 4.5 years examinations) was categorized as moderate (loss ≥10%), mild 5% to &lt;10%), stable (&lt;5% change) or gain (gain ≥5%). Participants were contacted every 4 months after examination ascertain vital status...